> top > projects > sonoma2 > docs > PubMed:16950808 > annotations
sonoma2  

PubMed:16950808 JSONTXT 2 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T0 0-9 MPA denotes Tolerance
T1 14-22 MPA denotes efficacy
T2 40-47 REG denotes changes
T3 57-74 CPA denotes B cell biomarkers
T4 92-114 CPA denotes systemic complications
T5 118-144 DISEASE denotes primary Sjögren's syndrome
T6 126-144 DISEASE denotes Sjögren's syndrome
T7 176-182 MPA denotes safety
T8 219-236 CPA denotes systemic symptoms
T9 254-280 DISEASE denotes primary Sjögren's syndrome
T10 261-279 DISEASE denotes Sjögren's syndrom
T11 282-285 DISEASE denotes pSS
T12 292-299 REG denotes changes
T13 303-320 CPA denotes B cell biomarkers
T14 376-379 DISEASE denotes pSS
T15 616-624 DISEASE denotes or lymph
T16 619-627 DISEASE denotes lymphoma
T17 637-665 DISEASE denotes refractory pulmonary disease
T18 645-662 DISEASE denotes ry pulmonary dise
T19 648-684 DISEASE denotes pulmonary disease with polysynovitis
T20 668-681 DISEASE denotes th polysynovi
T21 698-711 DISEASE denotes re polysynovi
T22 701-714 DISEASE denotes polysynovitis
T23 724-747 DISEASE denotes mixed cryoglobulinaemia
T24 727-744 DISEASE denotes ed cryoglobulinae
T25 754-770 DISEASE denotes ), thrombocytope
T26 757-773 DISEASE denotes thrombocytopenia
T27 783-805 DISEASE denotes nd mononeuritis multip
T28 786-808 DISEASE denotes mononeuritis multiplex
T29 893-904 REG denotes experienced
T30 940-968 DISEASE denotes serum sickness-like reaction
T31 978-986 POSREG denotes presence
T32 996-1008 GENE denotes antichimeric
T33 1021-1029 POSREG denotes Efficacy
T34 1047-1055 REG denotes observed
T35 1077-1086 DISEASE denotes th lympho
T36 1080-1089 DISEASE denotes lymphomas
T37 1119-1139 CPA denotes systemic involvement
T38 1141-1148 MPA denotes Dryness
T39 1153-1161 NEGREG denotes improved
T40 1194-1213 MPA denotes Corticosteroid dose
T41 1218-1225 NEGREG denotes reduced
T42 1246-1253 REG denotes induced
T43 1254-1263 NEGREG denotes decreased
T44 1261-1271 DISEASE denotes ed rheumat
T45 1264-1281 GENE denotes rheumatoid factor
T46 1283-1297 GENE denotes gamma-globulin
T47 1299-1318 GENE denotes nd beta2-microglobu
T48 1302-1321 GENE denotes beta2-microglobulin
T49 1322-1328 MPA denotes levels
T50 1338-1343 MPA denotes level
T51 1347-1371 GENE denotes B cell activating factor
T52 1376-1391 DISEASE denotes he tumour necro
T53 1407-1411 GENE denotes y (B
T54 1410-1414 GENE denotes BAFF
T55 1416-1425 POSREG denotes increased
T56 1426-1439 REG denotes concomitantly
T57 1445-1461 CPA denotes B cell depletion
T58 1499-1503 POSREG denotes good
T59 1504-1512 MPA denotes efficacy
T60 1557-1585 DISEASE denotes serum sickness-like reaction
T61 1610-1615 REG denotes shows
T62 1616-1620 POSREG denotes good
T63 1621-1629 MPA denotes efficacy
T64 1660-1677 CPA denotes systemic features
T65 1696-1702 REG denotes allows
T66 1716-1725 NEGREG denotes reduction
T67 1729-1747 MPA denotes corticosteroid use
T68 1756-1760 GENE denotes for
T69 1760-1764 GENE denotes BAFF
T70 1770-1775 MPA denotes level
T71 1785-1794 POSREG denotes increases
T72 1802-1818 CPA denotes B cell biomarker
T73 1819-1825 MPA denotes levels
T74 1826-1834 NEGREG denotes decrease
T75 1906-1914 POSREG denotes efficacy
T76 1925-1928 DISEASE denotes pSS
R0 T1 T2 ThemeOf efficacy,changes
R1 T3 T2 ThemeOf B cell biomarkers,changes
R10 T11 T7 ThemeOf pSS,safety
R11 T11 T8 ThemeOf pSS,systemic symptoms
R12 T11 T12 ThemeOf pSS,changes
R13 T13 T12 ThemeOf B cell biomarkers,changes
R14 T30 T29 ThemeOf serum sickness-like reaction,experienced
R15 T30 T31 ThemeOf serum sickness-like reaction,presence
R16 T32 T31 ThemeOf antichimeric,presence
R17 T33 T34 ThemeOf Efficacy,observed
R18 T36 T33 ThemeOf lymphomas,Efficacy
R19 T36 T34 ThemeOf lymphomas,observed
R2 T4 T2 ThemeOf systemic complications,changes
R20 T37 T34 ThemeOf systemic involvement,observed
R21 T38 T39 ThemeOf Dryness,improved
R22 T40 T41 ThemeOf Corticosteroid dose,reduced
R23 T49 T43 ThemeOf levels,decreased
R24 T45 T43 ThemeOf rheumatoid factor,decreased
R25 T45 T49 ThemeOf rheumatoid factor,levels
R26 T45 T50 ThemeOf rheumatoid factor,level
R27 T45 T55 ThemeOf rheumatoid factor,increased
R28 T46 T42 ThemeOf gamma-globulin,induced
R29 T46 T43 ThemeOf gamma-globulin,decreased
R3 T3 T4 ThemeOf B cell biomarkers,systemic complications
R30 T46 T49 ThemeOf gamma-globulin,levels
R31 T46 T50 ThemeOf gamma-globulin,level
R32 T46 T55 ThemeOf gamma-globulin,increased
R33 T48 T42 ThemeOf beta2-microglobulin,induced
R34 T48 T43 ThemeOf beta2-microglobulin,decreased
R35 T48 T49 ThemeOf beta2-microglobulin,levels
R36 T48 T50 ThemeOf beta2-microglobulin,level
R37 T48 T55 ThemeOf beta2-microglobulin,increased
R38 T49 T42 ThemeOf levels,induced
R39 T49 T55 ThemeOf levels,increased
R4 T5 T2 ThemeOf primary Sjögren's syndrome,changes
R40 T50 T43 ThemeOf level,decreased
R41 T50 T55 ThemeOf level,increased
R42 T50 T56 ThemeOf level,concomitantly
R43 T51 T43 ThemeOf B cell activating factor,decreased
R44 T51 T49 ThemeOf B cell activating factor,levels
R45 T51 T50 ThemeOf B cell activating factor,level
R46 T51 T55 ThemeOf B cell activating factor,increased
R47 T51 T56 ThemeOf B cell activating factor,concomitantly
R48 T54 T43 ThemeOf BAFF,decreased
R49 T54 T49 ThemeOf BAFF,levels
R5 T5 T3 ThemeOf primary Sjögren's syndrome,B cell biomarkers
R50 T54 T50 ThemeOf BAFF,level
R51 T54 T55 ThemeOf BAFF,increased
R52 T56 T55 ThemeOf concomitantly,increased
R53 T57 T56 ThemeOf B cell depletion,concomitantly
R54 T59 T58 ThemeOf efficacy,good
R55 T60 T58 ThemeOf serum sickness-like reaction,good
R56 T63 T61 ThemeOf efficacy,shows
R57 T63 T62 ThemeOf efficacy,good
R58 T67 T66 ThemeOf corticosteroid use,reduction
R59 T69 T70 ThemeOf BAFF,level
R6 T5 T4 ThemeOf primary Sjögren's syndrome,systemic complications
R60 T69 T71 ThemeOf BAFF,increases
R61 T70 T71 ThemeOf level,increases
R62 T72 T71 ThemeOf B cell biomarker,increases
R63 T72 T73 ThemeOf B cell biomarker,levels
R64 T72 T74 ThemeOf B cell biomarker,decrease
R65 T73 T71 ThemeOf levels,increases
R66 T73 T74 ThemeOf levels,decrease
R67 T76 T75 ThemeOf pSS,efficacy
R7 T9 T7 ThemeOf primary Sjögren's syndrome,safety
R8 T9 T8 ThemeOf primary Sjögren's syndrome,systemic symptoms
R9 T9 T12 ThemeOf primary Sjögren's syndrome,changes